<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">101244</article-id>
<article-id pub-id-type="doi">10.7554/eLife.101244</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101244.4</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.7</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>PA28γ promotes the malignant progression of tumor by elevating mitochondrial function via C1QBP</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Jiongke</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Shi</surname>
<given-names>Yujie</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Yingqiang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Huan</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Silu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yimei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6768-2382</contrib-id>
<name>
<surname>Zhou</surname>
<given-names>Xikun</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zeng</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>zengxin22@163.com</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5173-0781</contrib-id>
<name>
<surname>Li</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>lijing1984@scu.edu.cn</email>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Qianming</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pvqk557</institution-id><institution>State Key Laboratory of Oral Diseases &amp; National Center for Stomatology &amp; National Clinical Research Center for Oral Diseases &amp; Research Unit of Oral Carcinogenesis and Management &amp; Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University</institution></institution-wrap>, <city>Chengdu</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution>Department of Stomatology, The First Affiliated Hospital with Nanjing Medical University</institution>, <city>Nanjing</city>, <country country="CN">China</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00x43yy22</institution-id><institution>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy</institution></institution-wrap>, <city>Chengdu</city>, <country country="CN">China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Ali</surname>
<given-names>Sameh</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Children's Cancer Hospital Egypt</institution>
</institution-wrap>
<city>Cairo</city>
<country country="EG">Egypt</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>White</surname>
<given-names>Richard M</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Oxford</institution>
</institution-wrap>
<city>Oxford</city>
<country country="GB">United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>#</label><p>These authors contributed equally to this article.</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-10-01">
<day>01</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-06-10">
<day>10</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP101244</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-07-23">
<day>23</day>
<month>07</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-07-23">
<day>23</day>
<month>07</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.07.23.604769"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-10-01">
<day>01</day>
<month>10</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101244.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.101244.1.sa2">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101244.1.sa1">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101244.1.sa0">Reviewer #2 (Public review):</self-uri>
</event>
<event>
<event-desc>Reviewed preprint v2</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-11-15">
<day>15</day>
<month>11</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101244.2"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.101244.2.sa3">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101244.2.sa2">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101244.2.sa1">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.101244.2.sa0">Author response:</self-uri>
</event>
<event>
<event-desc>Reviewed preprint v3</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-03-12">
<day>12</day>
<month>03</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101244.3"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.101244.3.sa2">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101244.3.sa1">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.101244.3.sa0">Author response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Wang et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Wang et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-101244-v4.pdf"/>
<abstract>
<title>Abstract</title>
<p>Proteasome activator 28γ (PA28γ) plays a critical role in malignant progression of various tumors, however, its role and regulation are not well understood. Here, using oral squamous cell carcinoma (OSCC) as main research model, we discovered that PA28γ interacted with complement 1q binding protein (C1QBP), which is dependent on the N-terminus of C1QBP rather than the known functional domain (amino acids 168-213). Notably, we found that PA28γ enhances C1QBP protein stability in OSCC. Functionally, PA28γ contributes to the malignant progression of OSCC by affecting mitochondrial morphology and oxidative phosphorylation (OXPHOS) through C1QBP in vitro and vivo. Mechanically, PA28γ upregulates the expression of optic atrophy 1 (OPA1), mitofusin 1 (MFN1), mitofusin 2 (MFN2), and the mitochondrial respiratory complex via C1QBP. Moreover, in a clinical cohort of OSCC patients, PA28γ was positively correlated with C1QBP expression and negatively correlated with prognosis. Therefore, C1QBP represents a potential therapeutic target for cancer treatment and prognosis.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>oral squamous cell carcinoma</kwd>
<kwd>PA28γ</kwd>
<kwd>C1QBP</kwd>
<kwd>protein-protein interactions</kwd>
<kwd>mitochondria</kwd>
<kwd>oxidative phosphorylation</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>82072999</award-id>
</award-group>
<award-group id="funding-1a">
<funding-source>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>82273320</award-id>
</award-group>
<award-group id="funding-1b">
<funding-source>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>U19A2005</award-id>
</award-group>
<award-group id="funding-1c">
<funding-source>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>82270986</award-id>
</award-group>
<award-group id="funding-1d">
<funding-source>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>82201074</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>
<institution-wrap>
<institution>Province Natural Science Foundation of Sichuan</institution>
</institution-wrap>
</funding-source>
<award-id>23NSFSC0145</award-id>
</award-group>
<award-group id="funding-3">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/011ashp19</institution-id>
<institution>Innovation Research Project of Sichuan University</institution>
</institution-wrap>
</funding-source>
<award-id>2022SCUH0029</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>New data
(1) Figure 1J: Coimmunoprecipitation analysis demonstrated that mutations at C1QBPT76A and C1QBPG78N significantly reduced the binding ability to PA28γ.
(2) Appendix Figure 1J: AlphaFold 3 analysis suggested that the T76 and G78 residues of C1QBP may be key contributors to the interaction.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Proteasome activator 28γ (PA28γ), also known as REGγ or PSME3, is a well-known non-ATP-dependent proteasome regulator. PA28γ is overexpressed in several malignant tumors, including thyroid, colon, and breast cancer, and is significantly associated with poor prognosis (<xref ref-type="bibr" rid="c19">Mao, Liu, Li, &amp; Luo, 2008</xref>; <xref ref-type="bibr" rid="c28">Stadtmueller &amp; Hill, 2011</xref>). By regulating the stability of key components in various complex signaling pathways, PA28γ influences the biological behavior of tumor cells. Our previous studies revealed that the expression level of PA28γ in oral squamous cell carcinoma (OSCC) cancer nest tissues is positively correlated with patient prognosis (<xref ref-type="bibr" rid="c13">J. Li et al., 2015</xref>; <xref ref-type="bibr" rid="c18">S. Liu et al., 2018</xref>). However, its role and regulation are not well understood.</p>
<p>OSCC is the most common oral and maxillofacial malignant tumor(<xref ref-type="bibr" rid="c27">Siegel, Miller, Wagle, &amp; Jemal, 2023</xref>; <xref ref-type="bibr" rid="c29">Sung et al., 2021</xref>). The pathogenic factors of OSCC include smoking, alcohol consumption, and viral infections, such as human papillomavirus (HPV). Therapies for OSCC include surgery, radiotherapy, chemotherapy and immunotherapy. Despite the rapid development of imaging, surgery, radiotherapy and immunotherapy in recent years, along with the emphasis on personalized treatment and multidisciplinary cooperation in the treatment of OSCC, the overall survival rate of OSCC patients has not significantly improved (<xref ref-type="bibr" rid="c24">Peres et al., 2019</xref>). The main reasons for unsatisfactory treatment efficacy include invasion of surrounding tissue, early lymph node metastasis and a tendency toward recurrence (<xref ref-type="bibr" rid="c15">Lindemann, Takahashi, Patel, Osman, &amp; Myers, 2018</xref>). Metabolic reprogramming is a crucial characteristic of tumors, closely associated with malignant behaviors such as tumor growth, invasion, metastasis, and immune escape (<xref ref-type="bibr" rid="c22">Ohshima &amp; Morii, 2021</xref>). Current research on metabolic reprogramming in OSCC primarily focused on mechanism of glycolytic metabolism and metabolic shift from glycolysis to oxidative phosphorylation (OXPHOS) of oral squamous cell carcinoma, which lays the groundwork for novel therapeutic interventions to counteract OSCC (<xref ref-type="bibr" rid="c2">Chen et al., 2024</xref>; <xref ref-type="bibr" rid="c42">Zhang et al., 2020</xref>). Understanding the molecular events that lead to the occurrence and development of OSCC can aid in developing new tumor-targeted therapies, which hold significant clinical application potential.</p>
<p>The complement 1q binding protein (C1QBP) is a crucial protein for maintaining mitochondrial function, particularly in mitochondrial OXPHOS (<xref ref-type="bibr" rid="c7">Ghebrehiwet, Geisbrecht, Xu, Savitt, &amp; Peerschke, 2019</xref>; <xref ref-type="bibr" rid="c34">Q. Wang et al., 2022</xref>). OXPHOS is essential for the production of adenosine triphosphate (ATP), which is necessary for tumor development. C1QBP has been shown to play a significant role in cancer progression, as influencing tumor growth, invasion and metastasis (<xref ref-type="bibr" rid="c1">Bai et al., 2019</xref>; <xref ref-type="bibr" rid="c11">Hou, Lu, Wang, &amp; Yang, 2022</xref>; <xref ref-type="bibr" rid="c32">Vendramin et al., 2018</xref>). Due to these roles, C1QBP presents a promising therapeutic target for various tumors, including melanoma, breast cancer, and colorectal cancer (<xref ref-type="bibr" rid="c20">Matsumoto &amp; Bay, 2021</xref>). In OSCC, enhanced mitochondrial OXPHOS function might also be linked to malignant tumor progression (<xref ref-type="bibr" rid="c33">Vyas et al., 2021</xref>; <xref ref-type="bibr" rid="c39">Xiao et al., 2021</xref>; <xref ref-type="bibr" rid="c43">Zhu, Liu, Wu, &amp; Wang, 2021</xref>), although the underlying mechanism remain unclear.</p>
<p>In this study, we discovered that PA28γ interacts with C1QBP and that PA28γ can stabilize C1QBP. This interaction enhances OXPHOS and promotes the growth, migration and invasion of OSCC cells. Additionally, the expression of PA28γ and C1QBP is increased and positively correlated in OSCC. Therefore, PA28γ and C1QBP are potential targets for the treatment and prognosis of cancer. It is the first study to describe the undiscovered role of PA28γ in promoting the malignant progression of OSCC by elevating mitochondrial function, providing new clinical insights for the treatment of OSCC.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>PA28γ interacts with and stabilizes C1QBP</title>
<p>To explore how PA28γ promotes OSCC progression, we conducted a gene-gene interaction analysis using the GeneMANIA database. This analysis identified C1QBP as a significant gene within the interaction network, with the protein-coding gene of PA28γ also playing a key role in the C1QBP interaction network (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 1A, B</xref>). Subsequently, pull-down and coimmunoprecipitation analysis demonstrated that both endogenous and exogenous PA28γ and C1QBP could bind to each other (<xref rid="fig1" ref-type="fig">Fig. 1A, B</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 1 C, D</xref>). Moreover, the interaction of endogenous PA28γ and C1QBP was also proved by proximity ligation assay (PLA) (<xref rid="fig1" ref-type="fig">Fig. 1C</xref>). Then, we developed four OSCC cell lines with stable overexpression of PA28γ using a Flag-PA28γ-expressing lentivirus and observed that the protein level of C1QBP was higher in these cell lines compared to control cells (<xref rid="fig1" ref-type="fig">Fig. 1D</xref>). Notably, PA28γ upregulated C1QBP protein levels in a dose-dependent manner (<xref rid="fig1" ref-type="fig">Fig. 1E</xref>). To determine whether the upregulated C1QBP was due to increased stability, cells were pretreated with cycloheximide (CHX) to inhibit protein synthesis. As a result, in the presence of PA28γ, C1QBP exhibited a significantly lower turnover rate compared to the control group (<xref rid="fig1" ref-type="fig">Fig. 1F</xref>). In addition, PA28γ was able to stabilize C1QBP protein levels even in the presence of the proteasome inhibitor MG-132 (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 1E</xref>). Furthermore, pull-down analysis and structure prediction of biomolecular interactions with AlphaFold 3 revealed that the PA28γ-C1QBP interaction depends on the N-terminus (amino acids 1-167) of C1QBP, rather than the known functional domain (amino acids 168-213) that bind to mitochondrial antiviral proteins (<xref ref-type="bibr" rid="c23">Peerschke et al., 2020</xref>; <xref ref-type="bibr" rid="c40">Xu, Xiao, Liu, Ren, &amp; Gu, 2009</xref>) (<xref rid="fig1" ref-type="fig">Fig. 1G-I</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 1F-I</xref>). In addition, we employed AlphaFold 3 to perform energy minimization and predict hydrogen bonds between the C1QBP N-terminus (amino acids 1-167) and the PA28γ protein interaction region. The results suggest that the T76 and G78 residues of C1QBP may be key contributors to the interaction (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 1J</xref>). Consistently, coimmunoprecipitation analysis demonstrated that mutations at these sites (C1QBPT76A and C1QBPG78N) significantly reduced the binding ability to PA28γ (<xref rid="fig1" ref-type="fig">Fig. 1J</xref>). Therefore, our results illustrated that PA28γ could interacts with C1QBP, in a manner dependent on the N-terminus of C1QBP, and that PA28γ could stabilizes C1QBP.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Fig. 1</label>
<caption><title>The interaction between PA28γ and C1QBP.</title>
<p><bold>(A, B)</bold> The interaction between endogenous PA28γ and C1QBP in HSC-3 cells was verified via immunoprecipitation (IP). <bold>(C)</bold> PLA image of UM1 cells shows the interaction between C1QBP and PA28γ in both cytoplasm and nucleus (red fluorescence). <bold>(D)</bold> Western blot analysis of C1QBP in four OSCC cell lines with PA28γ-overexpressing. <bold>(E)</bold> Western blot analysis of C1QBP in 293T cells transfected with increasing doses of Flag-PA28γ. <bold>(F)</bold> 293T cells transfected with Flag-C1QBP with or without Myc-PA28γ were treated with CHX (100 μg/ml) for the indicated periods of time. Quantification of Flag-C1QBP levels relative to tubulin levels is shown (the data are representative of 1 experiment with 3 independent biological replicates, *<italic>P</italic>&lt;0.05). <bold>(G)</bold> Full-length C1QBP and truncation with deletion of functional domains. <bold>(H)</bold> Pull-down of 293T cells transfected with Myc-PA28γ and full-length Flag-C1QBP or truncation mutants of functional domains for 36h. <bold>(I)</bold> 293T cells transfected with Flag-C1QBP 94-282 with or without Myc-PA28γ were treated with CHX (100 μg/ml) for the indicated periods of time. <bold>(J)</bold> IP of 293T cells transfected with Flag-C1QBP wild type or mutations (T76A and G78N) for 48h.</p></caption>
<graphic xlink:href="604769v7_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>PA28γ and C1QBP colocalize in mitochondria and affect mitochondrial functions</title>
<p>To further investigate the physical interaction between PA28γ and C1QBP, we conducted an immunofluorescence (IF) assay in two OSCC cell lines, as shown these two proteins were colocalized in the mitochondria (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>). Remarkably, transmission electron microscopy (TEM) images revealed fewer mitochondrial vacuoles and higher mitochondrial ridge density in PA28γ-overexpressing cells compared to control cells (<xref rid="fig2" ref-type="fig">Fig. 2B</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 2A</xref>). IF analysis also showed increased mitochondrial lengths and areas in the PA28γ-overexpressing cells (<xref rid="fig2" ref-type="fig">Fig. 2C, D</xref>). Following that, we conducted a Cell Mito Stress Test to measure the oxygen consumption rate (OCR) (<xref rid="fig2" ref-type="fig">Fig. 2E, F</xref>). The results indicated significantly higher basal respiration, maximal OCRs and ATP production in PA28γ-overexpressing cells compared to control cells (<xref rid="fig2" ref-type="fig">Fig. 2G-I</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 2B-D</xref>). Considering that mitochondria are the primary site for ROS generation and that ROS play a crucial role in carcinogenesis, we measured ROS levels in OSCC cells. Consistently, ROS levels were significantly higher in PA28γ-overexpressing cells (<xref rid="fig2" ref-type="fig">Fig. 2J</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 2E</xref>). In addition, experiments conducted in PA28γ-sh OSCC cells yielded opposite results, further confirming these conclusions (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 2F-K</xref>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Fig. 2</label>
<caption><title>PA28γ and C1QBP colocalize in mitochondria and influence mitochondrial functions <italic>in vitro</italic>.</title>
<p><bold>(A)</bold> Confocal image of IF in two OSCC cell lines. <bold>(B)</bold> TEM images of PA28γ-overexpressing and control UM1 cells. <bold>(C)</bold> Representative confocal images of mitochondria in two OSCC cell lines. <bold>(D)</bold> The area and mean branch length of mitochondria in two OSCC cell lines were measured by ImageJ (the data are presented as the mean ± SD of 3 independent experiments; **P&lt;0.01, ***P&lt;0.001, and ****P&lt;0.0001). <bold>(E, F)</bold> OCRs of PA28γ-overexpressing and control UM1 and HN12 cells were plotted using a Cell Mito Stress Test Kit (the data are presented as the means ± SDs of 3 independent experiments). <bold>(G-I)</bold> Basal OCRs, maximal OCRs and ATP production of PA28γ-overexpressing and control UM1 cells measured by the Cell Mito Stress Test (the data are presented as the means ± SDs of 3 independent experiments, **<italic>P</italic>&lt;0.01). <bold>(J)</bold> ROS generation in PA28γ-overexpressing and control UM1 cells (the data are presented as the means ± SDs of 3 independent experiments; * <italic>P</italic>&lt;0.05).</p></caption>
<graphic xlink:href="604769v7_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To demonstrate the carcinogenic abilities of PA28γ and C1QBP, we injected 4MOSC2 cells, a mouse OSCC line, with or without Pa28γ overexpression under the surface of the tongue in C57BL/6 mice (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 3A</xref>). After 10 days of normal feeding, the tumors in the Pa28γ-overexpressing groups were significantly larger than those in the control group. Furthermore, via immunohistochemical (IHC) staining revealed that that PA28γ overexpression upregulate C1QBP in vivo (<xref rid="fig3" ref-type="fig">Fig. 3A-C</xref>). Consistent with the in vitro experiments, ATP production and ROS generation were significantly increased (<xref rid="fig3" ref-type="fig">Fig. 3D, E</xref>). Additionally, analysis of OSCC xenograft tumor tissue in nude mice revealed that PA28γ’s regulation of C1QBP in OSCC cells is independent of the immune system (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 3B, C</xref>). In addition, we established stable Pa28γ-silenced B16 cells, a mouse melanoma cell line, and found that the level of C1qbp protein was decreased in Pa28γ-silenced B16 cells (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 3D</xref>). Cells with or without Pa28γ silencing were grafted into the flanks of Pa28γ <sup>ko/ko</sup> and Pa28γ <sup>wt/wt</sup> C57BL/6 mice by subcutaneous injection (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 3E</xref>). Remarkably, the tumors derived from the silenced Pa28γ cells in Pa28γ <sup>ko/ko</sup> mice were smaller than those in the other groups (<xref rid="fig3" ref-type="fig">Fig. 3F-H</xref>). The trend of ATP and ROS was consistent with tumor size (<xref rid="fig3" ref-type="fig">Fig. 3I</xref>, J), and the protein levels of C1qbp in the tumors were also reduced in the Pa28γ-silenced groups (<xref rid="fig3" ref-type="fig">Fig. 3K</xref>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Fig. 3</label>
<caption><title>PA28γ affect mitochondrial functions <italic>in vivo</italic>.</title>
<p><bold>(A)</bold> Representative images of H&amp;E staining and IHC staining of C1qbp of tongue sections from mice (n=3). <bold>(B)</bold> Quantification of the sectional area in tumors from the Pa28γ-overexpressing and control groups (n=3; the data are presented as the means ± SDs of 3 samples; <italic>*P</italic>&lt;0.05). <bold>(C)</bold> Comparison of the immunoreactive scores (IRSs) of C1qbp antibody staining in the Pa28γ-overexpressing and control groups (n=3, the data are presented as the means ± SDs; *P&lt;0.05). <bold>(D, E)</bold> Quantification of ATP production and ROS levels in tumors from the Pa28γ-overexpressing and control groups (n=3; the data are presented as the means ± SDs of 3 samples; <italic>*P</italic>&lt;0.05, **<italic>*P</italic>&lt;0.001, <italic>****P</italic>&lt;0.0001). <bold>(F)</bold> Images of the tumors in different groups at the endpoint (n=6). <bold>(G-J)</bold> The volume, weight, ATP and ROS of tumors in different groups at the endpoint (n=6; the data are presented as the means ± SDs of 3 independent experiments; <italic>*P</italic>&lt;0.05, **P&lt;0.01, **<italic>*P</italic>&lt;0.001, <italic>****P</italic>&lt;0.0001). <bold>(K)</bold> Western blot analysis of tumors in different groups.</p></caption>
<graphic xlink:href="604769v7_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Collectively, these data suggest that PA28γ, which co-localizes with C1QBP in mitochondria, may involve in regulating mitochondrial morphology and function.</p>
</sec>
<sec id="s2c">
<title>PA28γ regulates mitochondrial OXPHOS by upregulating C1QBP</title>
<p>Due to the results of targeted metabolomics analysis by mass spectrometry (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 4A, B</xref>), it was found that PA28γ may affect the biological behavior and function of OSCC by influencing metabolism. Therefore, we explored the protein levels of the mitochondrial respiratory chain complex, C1QBP and other mitochondrial functional proteins. We found that the levels of C1QBP, complex I and IV proteins, as well as OPA1, MFN1 and MFN2 proteins, were upregulated in PA28γ-overexpressing OSCC cells (<xref rid="fig4" ref-type="fig">Fig. 4A, B</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 4C, D</xref>), These increases could be reversed by C1QBP silencing in PA28γ-overexpressing OSCC cells (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>).</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Fig. 4</label>
<caption><title>PA28γ regulates mitochondrial OXPHOS and cellular biological behavior via C1QBP.</title>
<p><bold>(A, B)</bold> Western blot analysis of PA28γ-overexpressing and control UM1 and 4MOSC2 cells. <bold>(C)</bold> Western blot analysis of PA28γ-overexpressing OSCC cells transfected with siNC or siC1QBP. <bold>(D)</bold> OCRs of C1QBP-silenced and control PA28γ-overexpressing UM1 and 4MOSC2 cells (the data are presented as the means ± SDs of 3 independent experiments). <bold>(E-H)</bold> Cell migration, invasion and proliferation in control, C1QBP-silenced, PA28γ-overexpressing and PA28γ-overexpressing + C1QBP-silenced UM1 cells (the data are presented as the means ± SDs of 3 independent experiments; *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, **<italic>*P</italic>&lt;0.001, <italic>****P</italic>&lt;0.0001).</p></caption>
<graphic xlink:href="604769v7_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Consistent with this, the OCRs of C1QBP-silenced PA28γ-overexpressing OSCC cells were markedly lower than those of control cells (<xref rid="fig4" ref-type="fig">Fig. 4D</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 4E-G</xref>). Subsequently, we constructed a series of experiments to detect the biological behavior of control and PA28γ-overexpressing OSCC cells with or without C1QBP silencing. C1QBP knockdown significantly attenuated the migration, invasive and proliferation capabilities previously augmented by PA28γ overexpression (<xref rid="fig4" ref-type="fig">Fig. 4E-H</xref>). These data suggest that PA28γ enhances mitochondrial OXPHOS function through C1QBP.</p>
</sec>
<sec id="s2d">
<title>C1QBP expression was positively associated with PA28γ expression and was associated with a worse prognosis in patients with OSCC or SKCM</title>
<p>To determine the correlation between PA28γ and C1QBP, IHC staining was performed in the clinical cohort of oral mucosa carcinogenesis. The results showed that both C1QBP and PA28γ were notably upregulated during the progression of oral mucosa carcinogenesis (<xref rid="fig5" ref-type="fig">Fig. 5A, B</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 5A</xref>), and the levels of PA28γ and C1QBP were positively related (<xref rid="fig5" ref-type="fig">Fig. 5C</xref>). Similarly, both C1QBP and PA28γ were upregulated in metastatic OSCC tissues (<xref rid="fig5" ref-type="fig">Fig. 5D, E</xref> and <xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 5B</xref>), and the levels of PA28γ and C1QBP were consistently positively correlated in OSCC cohort (<xref rid="fig5" ref-type="fig">Fig. 5F</xref>). Notably, consistent with our previous findings on PA28γ (<xref ref-type="bibr" rid="c13">J. Li et al., 2015</xref>), C1QBP or combining PA28γ and C1QBP could be a negative predator in our multicenter OSCC clinical cohort (<xref rid="fig5" ref-type="fig">Fig. 5G, H</xref>), TCGA HNSC database (<xref rid="fig5" ref-type="fig">Fig. 5I, J</xref>) and TCGA SKCM database (<xref ref-type="supplementary-material" rid="supp1">Appendix Fig. 5C, D</xref>).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Fig. 5</label>
<caption><title>The correlation between PA28γ and C1QBP in the carcinogenesis and development of OSCC.</title>
<p><bold>(A)</bold> Representative IHC staining of PA28γ and C1QBP in normal (n=8), OPMD (n=13) and OSCC (n=45) samples. <bold>(B)</bold> Comparison of the immunoreactive scores (IRSs) of C1QBP between the normal, OPMD and OSCC groups (the data are presented as the means ± SDs; <italic>*P</italic>&lt;0.05, *<italic>*P</italic>&lt;0.01, <italic>****P</italic>&lt;0.0001). <bold>(C)</bold> Spearman correlation analysis was used to test the correlation between PA28γ and C1QBP in normal, OPMD and OSCC tissues (<italic>P</italic>&lt;0.0001, <italic>r</italic>=0.8227). <bold>(D)</bold> Representative IHC staining of PA28γ and C1QBP in nonmetastatic (n=27) and metastatic (n=18) OSCC patients. <bold>(E)</bold> Comparison of the IRSs of C1QBP in the nonmetastatic and metastatic OSCC groups (the data are presented as the means ± SDs; <italic>*P</italic>&lt;0.05). <bold>(F)</bold> Spearman correlation analysis was used to test the correlation between PA28γ and C1QBP in OSCC tissues (<italic>P</italic>&lt;0.0001, <italic>r</italic>=0.6977). <bold>(G)</bold> Kaplan–Meier analysis of the protein expression of C1QBP in our multicenter OSCC clinical cohort (n=295, <italic>P</italic>=0.0480). <bold>(H)</bold> Kaplan–Meier analysis of both low or high protein expression of C1QBP and PA28γ in our multicenter OSCC clinical cohort (n=295, <italic>P</italic>=0.0100). <bold>(I)</bold> Kaplan–Meier analysis of the protein expression of C1QBP in TCGA HNSC database (n=259, <italic>P</italic>=0.025). <bold>(J)</bold> Kaplan–Meier analysis of both low or high protein expression of C1QBP and PA28γ in TCGA HNSC database (n=259, <italic>P</italic>=0.033).</p></caption>
<graphic xlink:href="604769v7_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Metabolic reprogramming is one of the hallmarks of malignant tumors and is related to the malignant biological behavior of tumors (<xref ref-type="bibr" rid="c5">Faubert, Solmonson, &amp; DeBerardinis, 2020</xref>; <xref ref-type="bibr" rid="c10">Hanahan, 2022</xref>; <xref ref-type="bibr" rid="c31">Tsai et al., 2023</xref>; <xref ref-type="bibr" rid="c38">Xia et al., 2021</xref>). The metabolic phenotype of tumor cells differs from that of normal cells and dynamically changes during tumor progression. OSCC is a common head and neck malignancy that is still a growing global health problem (<xref ref-type="bibr" rid="c12">Johnson et al., 2020</xref>). The development of OSCC is a complex and multifaceted process in which metabolic reprogramming appears to be important (<xref ref-type="bibr" rid="c16">B. Liu, Si, Wei, Zhang, &amp; Chen, 2023</xref>). However, the mechanism of metabolic reprogramming remains unclear. Excitingly, we found the evidence that PA28γ interacts with and stabilizes C1QBP. We speculate that aberrantly accumulated C1QBP enhances the function of mitochondrial OXPHOS and leads to the production of additional ATP and ROS by activating the expression and function of OPA1, MNF1, MFN2 and mitochondrial respiratory chain complex proteins. This process results in resulting in mitochondrial fusion and malignant tumor progression (<xref rid="fig6" ref-type="fig">Fig. 6</xref>). Our study highlights the underlying mechanism by which PA28γ participates in the regulation of OXPHOS by upregulating C1QBP in OSCC.</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Fig. 6</label>
<caption><title>Molecular mechanism through which PA28γ interacts with C1QBP in the malignant progression of tumor.</title>
<p>PA28γ can interacts with and stabilize C1QBP, which can activate the expression and function of OPA1, MNF1, MFN2 and mitochondrial respiratory chain complex proteins, resulting in enhanced mitochondrial OXPHOS, mitochondrial fusion and malignant tumor progression.</p></caption>
<graphic xlink:href="604769v7_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>C1QBP is also called gClqR, p32, p33 and HABP1, can be distributed inside cells, on the cell surface, and can also be secreted extracellularly (<xref ref-type="bibr" rid="c4">Egusquiza-Alvarez &amp; Robles-Flores, 2022</xref>). Within cells, C1QBP is primarily located in the mitochondria. The key functions of mitochondrial C1QBP include maintaining OXPHOS, supplying energy to cells, and achieving homeostasis of mitochondrial metabolism (<xref ref-type="bibr" rid="c7">Ghebrehiwet et al., 2019</xref>; <xref ref-type="bibr" rid="c34">Q. Wang et al., 2022</xref>). C1QBP is highly expressed in cells that require a large amount of energy, such as the heart, skeletal muscle, testis, ovary, small intestine and colon (<xref ref-type="bibr" rid="c6">Feichtinger et al., 2017</xref>). Sufficient energy is essential for cancer development, and C1QBP promotes malignant behaviors such as tumor invasion and metastasis by enhancing OXPHOS function in various cancers (<xref ref-type="bibr" rid="c26">Raschdorf et al., 2021</xref>; <xref ref-type="bibr" rid="c34">Q. Wang et al., 2022</xref>). However, there are no reports on the expression and functions of C1QBP in OSCC. In our study, we found the evidence that PA28γ interacts with and stabilizes C1QBP. As a proteasome activator, PA28γ usually affects the development of tumors by regulating the stability of various important proteins. For example, PA28γ can promote the degradation of p53, p21 leading to cancer progression (<xref ref-type="bibr" rid="c17">J. Liu et al., 2010</xref>). In addition, PA28γ can also play as a non-degradome role on tumor angiogenesis. For example, PA28γ can regulate the activation of NF-κB to promote the secretion of IL-6 and CCL2 in OSCC cells, thus promoting the angiogenesis of endothelial cells (<xref ref-type="bibr" rid="c18">S. Liu et al., 2018</xref>). However, the function of mitochondrial PA28γ may be differ from that of nuclear PA28γ (<xref ref-type="bibr" rid="c19">Mao et al., 2008</xref>). Our study reveals that PA28γ interacts with C1QBP and stabilizes C1QBP at the protein level. Therefore, we speculate that the binding sites of PA28γ and C1QBP may mask the specific post-translational modification sites of C1QBP and inhibit its degradation. For example, the transcriptional coactivator p300 interacts with Smad7 by acetylating two lysine residues in its N-terminus, which stabilize Smad7 and protect it from TGFβ-induced degradation (<xref ref-type="bibr" rid="c9">Grönroos, Hellman, Heldin, &amp; Ericsson, 2002</xref>). Overall, the specific mechanism involved in the interaction between PA28γ and C1QBP still needs further exploration.</p>
<p>Considering that C1QBP is a vital protein for maintaining mitochondrial metabolism (<xref ref-type="bibr" rid="c30">Tian et al., 2023</xref>), we further investigated the function underlying the malignant progression of OSCC through the interaction between PA28γ and C1QBP in vitro and in vivo. PA28γ and C1QBP colocalized in the mitochondria, and the stabilization of C1QBP by PA28γ enhanced mitochondrial morphology and OXPHOS. This enhancement is crucial for ATP production, and ATP is the primary energy currency of cellular metabolism. Therefore, PA28γ’s regulation of OXPHOS may impact cellular energy metabolism. PA28γ has been reported to activate the mTORC1 signaling pathway in hepatocellular carcinoma cells to promote glycolysis and inhibit OXPHOS (<xref ref-type="bibr" rid="c41">Yao et al., 2021</xref>). These findings contrast with our study, potentially due to organ heterogeneity or the complexity of metabolic reprogramming.</p>
<p>In the tissue microenvironment of oral lichen planus, a potentially malignant oral disorder, PA28γ in epithelial cells can regulate T cell differentiation (<xref ref-type="bibr" rid="c35">Y. Wang et al., 2024</xref>), while PA28γ in CAFs is involved in the crosstalk between stromal cells and tumor cells (<xref ref-type="bibr" rid="c14">Z. Li et al., 2024</xref>). This suggests that PA28γ may interact with the tumor immune microenvironment. Our phenotypically similar OSCC xenograft tumor models in both immunocompetent and nude mice indicate that the regulation of mitochondrial OXPHOS by PA28γ localized in tumor cell mitochondria does not entirely depend on the immune system (<xref ref-type="bibr" rid="c36">Z. Wang et al., 2019</xref>).</p>
<p>Furthermore, our study reveals that PA28γ can regulate C1QBP and influence mitochondrial morphology and function by enhancing the expression of OPA1, MFN1, MFN2 and the mitochondrial respiratory complex. Mitochondrial fusion, crucial for oxidative metabolism and cell proliferation, is regulated by MFN1, MFN2, and OPA1. The first two fuse with the outer mitochondrial membrane, while the last fuses with the inner mitochondrial membrane (<xref ref-type="bibr" rid="c37">Westermann, 2010</xref>). OPA1 is an essential inner mitochondrial membrane protein with multiple functions, including regulating mitochondrial fusion, crest morphology, mtDNA stability, and interacting with the mitochondrial respiratory chain to regulate OXPHOS (<xref ref-type="bibr" rid="c3">Del Dotto et al., 2018</xref>).</p>
<p>Finally, we analyzed the expression patterns and significance of PA28γ and C1QBP in a clinical cohort. PA28γ and C1QBP were negatively correlated with prognosis in the OSCC clinical cohort. Notably, some studies have shown that OXPHOS is upregulated in various tumors, with some advanced tumors preferring OXPHOS metabolically (<xref ref-type="bibr" rid="c22">Ohshima &amp; Morii, 2021</xref>; <xref ref-type="bibr" rid="c25">Qiu, Li, &amp; Zhang, 2023</xref>). OXPHOS activity is associated with the recurrence of OSCC (<xref ref-type="bibr" rid="c21">Noh et al., 2023</xref>). Additionally, the enhancement of OXPHOS and ATP production by ROS proto-oncogene 1, which localizes to mitochondria in OSCC, promotes the OSCC invasion(<xref ref-type="bibr" rid="c21">Noh et al., 2023</xref>; <xref ref-type="bibr" rid="c8">Grimm et al., 2014</xref>). These findings are consistent with our results. Our study not only explain the mechanisms and signaling networks underlying the oncogenic potential of PA28γ but also contribute to understanding the possible mechanisms involved in OSCC metabolic reprogramming.</p>
<p>In summary, we found that PA28γ could interact with C1QBP and stabilize C1QBP. This enhances the function of OXPHOS, leading to increased production of ATP and ROS by activating the expression and function of OPA1, MNF1, MFN2 and the mitochondrial respiratory chain complex. This process promotes mitochondrial fusion and malignant tumor progression. The expression of PA28γ and C1QBP was increased and positively correlated in OSCC. High expression of PA28γ and C1QBP was correlated with poor prognosis in OSCC patients, indicating that both factors could serve as potential targets for the treatment and prognosis of OSCC.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>Patients and Follow-up</title>
<p>Our study included 4 cohorts. The first cohort included 8 normal controls, 13 patients with oral potentially malignant disorder (OPMD), and 45 patients with OSCC (Appendix Table 1). These patients visited the West China Hospital of Stomatology in 2021. The normal tissues were obtained from patients who underwent maxillofacial plastic surgery. The second cohort for survival analysis included 295 patients diagnosed with primary OSCC tumors who visited West China Hospital of Stomatology, Peking University Hospital of Stomatology and Guangdong Provincial Stomatological Hospital from 2005 to 2009 (Appendix Table 2). None of the patients had cancer in other organs. These patients received regular follow-up for 1-133 months after the operation. The protocol of this study was approved by the ethics committee of the West China Hospital of Stomatology (Approval number: WCHSIRB-D-2020-046). The third cohort, comprising 518 patients with head and neck squamous cell carcinoma (HNSCC), was obtained from The Cancer Genome Atlas (TCGA) database (Appendix Table 3). The last cohort, comprising 458 patients with skin cutaneous melanoma (SKCM), was obtained from TCGA database (Appendix Table 4).</p>
</sec>
<sec id="s4b">
<title>Laboratory Experiments</title>
<p>All animal studies were approved by the Animal Care and Use Committee for the State Key Laboratory of Oral Diseases (Approval number: WCHSIRB-D-2022-032) in compliance with the Guide for the updated Animal Research: Reporting of In Vivo Experiments (ARRIVE) 2.0 guidelines. Other methods are detailed in the Supplemental Materials and Methods, including cell culture and cell-related experiments, animal models, mitochondrial function detection, western blot/immunoprecipitation assays, hematoxylin and eosin (H&amp;E) staining, and immunohistochemistry.</p>
</sec>
<sec id="s4c">
<title>Statistical Analysis</title>
<p>The data were analyzed using GraphPad Prism software version 8.0. The statistical data are expressed as the mean ± standard deviation (SD). Chi-square and Fisher exact tests, Spearman correlation tests, Wilcoxon rank-sum tests, one-way ANOVA and Student’s t tests were used to analyze the data. The Kaplan-Meier method was used for survival analysis, and the log-rank test was used to evaluate the prognostic value of C1QBP in OSCC patients. The data are shown as the mean ± standard error, and a value of <italic>P</italic>&lt;0.05 was considered to indicate statistical significance: <italic>P</italic>&lt;0.05*, <italic>P</italic>&lt;0.01**, <italic>P</italic>&lt;0.001***, and <italic>P</italic>&lt;0.0001****. Each experiment was repeated 3 times.</p>
</sec>
</sec>

</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by grants from the National Natural Science Foundation of China (82072999 and 82273320 to J. Li, U19A2005 and 82270986 to X. Zeng, 82201074 to J. Wang), the Province Natural Science Foundation of Sichuan (23NSFSC0145 to J. Li), and the Innovation Research Project of Sichuan University (2022SCUH0029 to J. Li). The authors thank Zhijun Sun (School and Hospital of Stomatology, Wuhan University) for providing the cells needed for the experiment and Ning Ji (State Key Laboratory of Oral Diseases, Sichuan University) for excellent assistance with microscopic imaging.</p>
</ack>
<sec id="d1e1234" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Author contributions</title>
<p>J. Wang, Y. Shi, X. Zeng, J. Li contributed to conception and design, data acquisition, analysis, and interpretation, drafted and critically revised the manuscript; Y. Wang, Y. Shen, H Liu contributed to data acquisition; S. Sun, Y. Wang contributed to data analysis and interpretation; X. Zhou, Q. Chen contributed to conception and design, critically revised the manuscript. All the authors gave final approval and agreed to be accountable for all aspects of the work.</p>
</sec>
</sec>
<sec id="suppd1e1234" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="supp1">
<label>Supplemental Materials and Methods</label>
<media xlink:href="supplements/604769_file08.docx"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bai</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zhan</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>M.</given-names></string-name>, <etal>…</etal> <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2019</year>). <article-title>C1QBP Promotes Homologous Recombination by Stabilizing MRE11 and Controlling the Assembly and Activation of MRE11/RAD50/NBS1 Complex</article-title>. <source>Mol Cell</source>, <volume>75</volume>(<issue>6</issue>): <fpage>1299</fpage>-<lpage>1314.e1296</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molcel.2019.06.023</pub-id></mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ling</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>D.</given-names></string-name>, <etal>…</etal> <string-name><surname>Cao</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2024</year>). <article-title>Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma</article-title>. <source>Transl Res</source>. <volume>268</volume>:<fpage>28</fpage>–<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.trsl.2024.01.009</pub-id>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Del Dotto</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Fogazza</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lenaers</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Rugolo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Carelli</surname>, <given-names>V.</given-names></string-name>, &amp; <string-name><surname>Zanna</surname>, <given-names>C.</given-names></string-name></person-group> (<year>2018</year>). <article-title>OPA1: How much do we know to approach therapy?</article-title> <source>Pharmacol Res</source>, <volume>131</volume>:<fpage>199</fpage>–<lpage>210</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2018.02.018</pub-id></mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Egusquiza-Alvarez</surname>, <given-names>C. A.</given-names></string-name>, &amp; <string-name><surname>Robles-Flores</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2022</year>). <article-title>An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer</article-title>. <source>J Cancer Res Clin Oncol</source>, <volume>148</volume>(<issue>8</issue>):<fpage>1831</fpage>–<lpage>1854</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00432-022-04001-5</pub-id></mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Faubert</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Solmonson</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>DeBerardinis</surname>, <given-names>R. J.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Metabolic reprogramming and cancer progression</article-title>. <source>Science</source>, <volume>368</volume>(<issue>6487</issue>):<fpage>eaaw5473</fpage>‥ doi:<pub-id pub-id-type="doi">10.1126/science.aaw5473</pub-id></mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feichtinger</surname>, <given-names>R. G.</given-names></string-name>, <string-name><surname>Oláhová</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kishita</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Garone</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kremer</surname>, <given-names>L. S.</given-names></string-name>, <string-name><surname>Yagi</surname>, <given-names>M.</given-names></string-name>, <etal>…</etal> <string-name><surname>Prokisch</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2017</year>). <article-title>Biallelic C1QBP Mutations Cause Severe Neonatal-, Childhood-, or Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain Deficiencies</article-title>. <source>The American Journal of Human Genetics</source>, <volume>101</volume>(<issue>4</issue>): <fpage>525</fpage>–<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.08.015</pub-id></mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghebrehiwet</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Geisbrecht</surname>, <given-names>B. V.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Savitt</surname>, <given-names>A. G.</given-names></string-name>, &amp; <string-name><surname>Peerschke</surname>, <given-names>E. I. B.</given-names></string-name></person-group> (<year>2019</year>). <article-title>The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)</article-title>. <source>Semin Immunol</source>, <volume>45</volume>:<fpage>101338</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2019.101338</pub-id></mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grimm</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cetindis</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lehmann</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Biegner</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Munz</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Teriete</surname>, <given-names>P.</given-names></string-name>, <etal>…</etal> <string-name><surname>Reinert</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?</article-title> <source>Journal of Translational Medicine</source>, <volume>12</volume>(<issue>1</issue>):<fpage>208</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1479-5876-12-208</pub-id></mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grönroos</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Hellman</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Heldin</surname>, <given-names>C. H.</given-names></string-name>, &amp; <string-name><surname>Ericsson</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2002</year>). <article-title>Control of Smad7 stability by competition between acetylation and ubiquitination</article-title>. <source>Mol Cell</source>, <volume>10</volume>(<issue>3</issue>):<fpage>483</fpage>–<lpage>493</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1097-2765(02)00639-1</pub-id></mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanahan</surname>, <given-names>D.</given-names></string-name></person-group> (<year>2022</year>). <article-title>Hallmarks of Cancer: New Dimensions</article-title>. <source>Cancer Discov</source>, <volume>12</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.cd-21-1059</pub-id></mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hou</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, &amp; <string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name></person-group> (<year>2022</year>). <article-title>The Mitochondrial Protein C1QBP Promotes Hepatocellular Carcinoma Progression by Enhancing Cell Survival, Migration and Invasion</article-title>. <source>J Cancer</source>, <volume>13</volume>(<issue>8</issue>):<fpage>2477</fpage>–<lpage>2489</lpage>. doi:<pub-id pub-id-type="doi">10.7150/jca.69379</pub-id></mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname>, <given-names>D. E.</given-names></string-name>, <string-name><surname>Burtness</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Leemans</surname>, <given-names>C. R.</given-names></string-name>, <string-name><surname>Lui</surname>, <given-names>V. W. Y.</given-names></string-name>, <string-name><surname>Bauman</surname>, <given-names>J. E.</given-names></string-name>, &amp; <string-name><surname>Grandis</surname>, <given-names>J. R.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Head and neck squamous cell carcinoma</article-title>. <source>Nat Rev Dis Primers</source>, <volume>6</volume>(<issue>1</issue>):<fpage>92</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41572-020-00224-3</pub-id></mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>H.</given-names></string-name>, <etal>…</etal> <string-name><surname>Chen</surname>, <given-names>Q.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Associations between proteasomal activator PA28γ and outcome of oral squamous cell carcinoma: Evidence from cohort studies and functional analyses</article-title>. <source>EBioMedicine</source>, <volume>2</volume>(<issue>8</issue>):<fpage>851</fpage>–<lpage>858</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2015.07.004</pub-id></mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hua</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>Y.</given-names></string-name>, <etal>…</etal> <string-name><surname>Li</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2024</year>). <article-title>PA28γ coordinates the cross-talk between cancer-associated fibroblasts and tumor cells to promote OSCC progression via HDAC1/E2F3/IGF2 signaling</article-title>. <source>Cancer Lett</source>, <volume>594</volume>:<fpage>216962</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2024.216962</pub-id>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindemann</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Takahashi</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Osman</surname>, <given-names>A. A.</given-names></string-name>, &amp; <string-name><surname>Myers</surname>, <given-names>J. N.</given-names></string-name></person-group> (<year>2018</year>). <article-title>Targeting the DNA Damage Response in OSCC with TP53 Mutations</article-title>. <source>J Dent Res</source>, <volume>97</volume>(<issue>6</issue>):<fpage>635</fpage>–<lpage>644</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0022034518759068</pub-id></mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Si</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, &amp; <string-name><surname>Chen</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2023</year>). <article-title>PTP4A1 promotes oral squamous cell carcinoma (OSCC) metastasis through altered mitochondrial metabolic reprogramming</article-title>. <source>Cell Death Discov</source>, <volume>9</volume>(<issue>1</issue>):<fpage>360</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41420-023-01657-x</pub-id></mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <etal>…</etal> <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name></person-group> (<year>2010</year>). <article-title>REGgamma modulates p53 activity by regulating its cellular localization</article-title>. <source>J Cell Sci</source>, <volume>123</volume>:<fpage>4076</fpage>–<lpage>4084</lpage>. doi:<pub-id pub-id-type="doi">10.1242/jcs.067405</pub-id></mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>J.</given-names></string-name>, <etal>…</etal> <string-name><surname>Chen</surname>, <given-names>Q.</given-names></string-name></person-group> (<year>2018</year>). <article-title>PA28γ acts as a dual regulator of IL-6 and CCL2 and contributes to tumor angiogenesis in oral squamous cell carcinoma</article-title>. <source>Cancer Lett</source>, <volume>428</volume>:<fpage>192</fpage>–<lpage>200</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2018.04.024</pub-id></mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mao</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, &amp; <string-name><surname>Luo</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2008</year>). <article-title>REGgamma, a proteasome activator and beyond?</article-title> <source>Cell Mol Life Sci</source>, <volume>65</volume>(<issue>24</issue>):<fpage>3971</fpage>–<lpage>3980</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-008-8291-z</pub-id></mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matsumoto</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Bay</surname>, <given-names>B. H.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers</article-title>. <source>Curr Med Chem</source>, <volume>28</volume>(<issue>25</issue>):<fpage>5048</fpage>–<lpage>5065</lpage>. doi:<pub-id pub-id-type="doi">10.2174/0929867328666201231124038</pub-id></mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noh</surname>, <given-names>J. K.</given-names></string-name>, <string-name><surname>Woo</surname>, <given-names>S. R.</given-names></string-name>, <string-name><surname>Kong</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>M. K.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>Y. C.</given-names></string-name>, <etal>…</etal> <string-name><surname>Eun</surname>, <given-names>Y. G.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation</article-title>. <source>Mol Oncol</source>, <volume>17</volume>(<issue>1</issue>):<fpage>134</fpage>–<lpage>149</lpage>. doi:<pub-id pub-id-type="doi">10.1002/1878-0261.13328</pub-id></mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ohshima</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Morii</surname>, <given-names>E.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis</article-title>. <source>Metabolites</source>, <volume>11</volume>(<issue>1</issue>):<fpage>28</fpage>. doi:<pub-id pub-id-type="doi">10.3390/metabo11010028</pub-id></mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peerschke</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Stier</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Kandov</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>de Stanchina</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Adusumilli</surname>, <given-names>P. S.</given-names></string-name></person-group> (<year>2020</year>). <article-title>gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma</article-title>. <source>Front Oncol</source>, <volume>10</volume>:<fpage>1413</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2020.01413</pub-id></mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peres</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Macpherson</surname>, <given-names>L. M. D.</given-names></string-name>, <string-name><surname>Weyant</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Daly</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Venturelli</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Mathur</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Watt</surname>, <given-names>R. G.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Oral diseases: a global public health challenge</article-title>. <source>Lancet</source>, <volume>394</volume>(<issue>10194</issue>):<fpage>249</fpage>–<lpage>260</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(19)31146-8</pub-id></mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, &amp; <string-name><surname>Zhang</surname>, <given-names>Z.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection</article-title>. <source>Cell Oncol (Dordr)</source>, <volume>46</volume>(<issue>4</issue>):<fpage>847</fpage>–<lpage>865</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13402-023-00801-0</pub-id></mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raschdorf</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sünderhauf</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Skibbe</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ghebrehiwet</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Peerschke</surname>, <given-names>E. I.</given-names></string-name>, <string-name><surname>Sina</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name><surname>Derer</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Heterozygous P32/C1QBP/HABP1 Polymorphism rs56014026 Reduces Mitochondrial Oxidative Phosphorylation and Is Expressed in Low-grade Colorectal Carcinomas</article-title>. <source>Frontiers in Oncology</source>, <volume>10</volume>:<fpage>631592</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2020.631592</pub-id></mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname>, <given-names>R. L.</given-names></string-name>, <string-name><surname>Miller</surname>, <given-names>K. D.</given-names></string-name>, <string-name><surname>Wagle</surname>, <given-names>N. S.</given-names></string-name>, &amp; <string-name><surname>Jemal</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Cancer statistics, 2023</article-title>. <source>CA Cancer J Clin</source>, <volume>73</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21763</pub-id></mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stadtmueller</surname>, <given-names>B. M.</given-names></string-name>, &amp; <string-name><surname>Hill</surname>, <given-names>C. P.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Proteasome Activators</article-title>. <source>Molecular Cell</source>, <volume>41</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molcel.2010.12.020</pub-id></mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ferlay</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Siegel</surname>, <given-names>R. L.</given-names></string-name>, <string-name><surname>Laversanne</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Soerjomataram</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Jemal</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Bray</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA Cancer J Clin</source>, <volume>71</volume>(<issue>3</issue>):<fpage>209</fpage>–<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21660</pub-id></mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Chai</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Jiang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitness</article-title>. <source>Cancer Immunol Immunother</source>, <volume>72</volume>(<issue>7</issue>):<fpage>2151</fpage>–<lpage>2168</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-023-03407-5</pub-id></mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsai</surname>, <given-names>C. H.</given-names></string-name>, <string-name><surname>Chuang</surname>, <given-names>Y. M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>Y. R.</given-names></string-name>, <string-name><surname>Tzeng</surname>, <given-names>S. F.</given-names></string-name>, <string-name><surname>Teoh</surname>, <given-names>S. T.</given-names></string-name>, <etal>…</etal> <string-name><surname>Ho</surname>, <given-names>P. C.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Immunoediting instructs tumor metabolic reprogramming to support immune evasion</article-title>. <source>Cell Metab</source>, <volume>35</volume>(<issue>1</issue>):<fpage>118</fpage>-<lpage>133.e117</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2022.12.003</pub-id></mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vendramin</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Verheyden</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Ishikawa</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Goedert</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Nicolas</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Saraf</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Leucci</surname>, <given-names>E.</given-names></string-name></person-group> (<year>2018</year>). <article-title>SAMMSON fosters cancer cell fitness by concertedly enhancing mitochondrial and cytosolic translation</article-title>. <source>Nat Struct Mol Biol</source>, <volume>25</volume>(<issue>11</issue>):<fpage>1035</fpage>–<lpage>1046</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41594-018-0143-4</pub-id></mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vyas</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Harbison</surname>, <given-names>R. A.</given-names></string-name>, <string-name><surname>Faden</surname>, <given-names>D. L.</given-names></string-name>, <string-name><surname>Kubik</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Palmer</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Q.</given-names></string-name>, <etal>…</etal> <string-name><surname>Duvvuri</surname>, <given-names>U.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation</article-title>. <source>Clin Cancer Res</source>, <volume>27</volume>(<issue>22</issue>):<fpage>6250</fpage>–<lpage>6264</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.ccr-20-4789</pub-id></mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Chai</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Sobhani</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Neeli</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Tian</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2022</year>). <article-title>C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response</article-title>. <source>Front Physiol</source>, <volume>13</volume>:<fpage>1012112</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphys.2022.1012112</pub-id></mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>S.</given-names></string-name>, <etal>…</etal> <string-name><surname>Li</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2024</year>). <article-title>PA28γ induces dendritic cell maturation and activates TDcell immune responses in oral lichen planus</article-title>. <source>MedComm</source>, <volume>5</volume>(<issue>5</issue>):<fpage>e561</fpage>. doi:<pub-id pub-id-type="doi">10.1002/mco2.561</pub-id></mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>V. H.</given-names></string-name>, <string-name><surname>Allevato</surname>, <given-names>M. M.</given-names></string-name>, <string-name><surname>Gilardi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Luis Callejas-Valera</surname>, <given-names>J.</given-names></string-name>, <etal>…</etal> <string-name><surname>Gutkind</surname>, <given-names>J. S.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4</article-title>. <source>Nat Commun</source>, <volume>10</volume>(<issue>1</issue>):<fpage>5546</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-13471-0</pub-id></mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Westermann</surname>, <given-names>B.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Mitochondrial fusion and fission in cell life and death</article-title>. <source>Nature Reviews Molecular Cell Biology</source>, <volume>11</volume>(<issue>12</issue>):<fpage>872</fpage>–<lpage>884</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrm3013</pub-id></mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Oyang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>N.</given-names></string-name>, <etal>…</etal> <string-name><surname>Liao</surname>, <given-names>Q.</given-names></string-name></person-group> (<year>2021</year>). <article-title>The cancer metabolic reprogramming and immune response</article-title>. <source>Mol Cancer</source>, <volume>20</volume>(<issue>1</issue>):<fpage>28</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12943-021-01316-8</pub-id></mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Peng</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>L.</given-names></string-name>, <etal>…</etal> <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2021</year>). <article-title>TRAP1 suppresses oral squamous cell carcinoma progression by reducing oxidative phosphorylation metabolism of Cancer-associated fibroblasts</article-title>. <source>BMC Cancer</source>, <volume>21</volume>(<issue>1</issue>):<fpage>1329</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-021-09049-z</pub-id></mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Xiao</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ren</surname>, <given-names>H.</given-names></string-name>, &amp; <string-name><surname>Gu</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2009</year>). <article-title>Inhibition of RIG-I and MDA5-dependent antiviral response by gC1qR at mitochondria</article-title>. <source>Proc Natl Acad Sci USA</source>, <volume>106</volume>(<issue>5</issue>):<fpage>1530</fpage>–<lpage>1535</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0811029106</pub-id></mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yao</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Xuan</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>T.</given-names></string-name>, <etal>…</etal> <string-name><surname>Zhang</surname>, <given-names>B.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma</article-title>. <source>Oncogene</source>, <volume>40</volume>(<issue>3</issue>):<fpage>677</fpage>–<lpage>692</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41388-020-01558-8</pub-id></mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Rajthala</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sapkota</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Dongre</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Parajuli</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Liang</surname>, <given-names>X.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Metabolic reprogramming of normal oral fibroblasts correlated with increased glycolytic metabolism of oral squamous cell carcinoma and precedes their activation into carcinoma associated fibroblasts</article-title>. <source>Cell Mol Life Sci</source>, <volume>77</volume>(<issue>6</issue>):<fpage>1115</fpage>–<lpage>1133</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-019-03209-y</pub-id></mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Wang</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Association Between Mitochondrial DNA Copy Number and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Dose-Response Meta-Analysis</article-title>. <source>Med Sci Monit</source>, <volume>27</volume>:<fpage>e928327</fpage>. doi:<pub-id pub-id-type="doi">10.12659/msm.928327</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101244.4.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ali</surname>
<given-names>Sameh</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Children's Cancer Hospital Egypt</institution>
</institution-wrap>
<city>Cairo</city>
<country>Egypt</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>This manuscript determines how PA28g, a proteasome regulator that is overexpressed in tumors, and C1QBP, a mitochondrial protein for maintaining oxidative phosphorylation that plays a role in tumor progression, interact in tumor cells to promote their growth, migration and invasion. Additional experiments and analyses that supported the theoretical models for the interaction have been performed in response to the reviews. The overall findings and conceptual framework are <bold>important</bold> and the evidence is <bold>solid</bold>. A logical extrapolation of this work is to test the C1QBP mutants using functional assays to determine whether the mutations can decrease the protein stability mediated by the interaction with PA28g.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101244.4.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors tried to determine how PA28g functions in oral squamous cell carcinoma (OSCC) cells. They hypothesized it may act through metabolic reprogramming in the mitochondria.</p>
<p>Strengths:</p>
<p>They found that the genes of PA28g and C1QBP are in an overlapping interaction network after an analysis of a genome database. They also found that the two proteins interact in coimmunoprecipitation and pull-down assays using the lysate from OSCC cells with or without expression of the exogenous genes. They used truncated C1QBP proteins to map the interaction site to the N-terminal 167 residues of C1QBP protein. They observed the levels of the two proteins are positively correlated in the cells. They provided evidence for the colocalization of the two proteins in the mitochondria and the effect on mitochondrial form and function in vitro and in vivo OSCC models, and the correlation of the protein expression with the prognosis of cancer patients.</p>
<p>Comments on revision:</p>
<p>The third revision added data from two point mutations of C1QBP that would disrupt a hydrogen bond network with PA28g protein. As one would expect from the structural models obtained with AlphaFold, the interaction between the two proteins as detected by co-immunoprecipitation of cell lysate was reduced by both mutations. Therefore, the theoretical models for the interaction were supported by the experimental data. Moving forward, the home run experiments would be to test the C1QBP mutants in functional assays to determine whether the mutations can decrease the protein stability afforded by the interaction with PA28g, which in turn decrease the effect of PA28g on mitochondria and tumor cells via C1QBP. Success of these experiments will conclude this manuscript that presents a novel finding for tumor cell biology which could be a launch pad for therapeutic intervention of tumor development.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101244.4.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jiongke</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Yujie</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ying</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Yingqiang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Huan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Silu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yimei</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Xikun</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6768-2382</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Yu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zeng</surname>
<given-names>Xin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jing</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5173-0781</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Qianming</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the previous reviews</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>This manuscript determines how PA28g, a proteasome regulator that is overexpressed in tumors, and C1QBP, a mitochondrial protein for maintaining oxidative phosphorylation that plays a role in tumor progression, interact in tumor cells to promote their growth, migration and invasion. Evidence for the interaction and its impact on mitochondrial form and function was provided although it is not particularly strong.</p>
<p>The revised manuscript corrected mislabeled data in figures and provides more details in figure legends. Misleading sentences and typos were corrected. However, key experiments that were suggested in previous reviews were not done, such as making point mutations to disrupt the protein interactions and assess the consequence on protein stability and function. Results from these experiments are critical to determine whether the major conclusions are fully supported by the data.</p>
<p>The second revision of the manuscript included the proximity ligation data to support the PA28g-C1QBP interaction in cells. However, the method and data were not described in sufficient detail for readers to understand. The revision also includes the structural models of the PA28g-C1QBP complex predicted by AlphaFold. However, the method and data were not described with details for readers to understand how this structural modeling was done, what is the quality of the resulting models, and the physical nature of the protein-protein interaction such as what kind of the non-covalent interactions exist in the interface of the protein complexes. Furthermore, while the interactions mediated by the protein fragments were tested by pull-down experiments, the interactions mediated by the three residues were not tested by mutagenesis and pull-down experiments. In summary, the revision was improved, but further improvement is needed.</p>
</disp-quote>
<p>Thank you very much for your comments.</p>
<p>(1) Based on your suggestion, we predicted the possible interaction sites using AlphaFold 3 and found that mutations in amino acids 76 and 78 of C1QBP affect the interaction with PA28γ (Revised Appendix Figure 1J). Subsequently, pulldown experiment also found that after mutating the amino acids at the two aforementioned sites (T76A, G78N), C1QBP that could bind to PA28γ decreased (Revised Figure 1J). The above results confirm that PA28γ could interacts with C1QBP, in a manner dependent on the N-terminus of C1QBP. These findings are now included in the revised manuscript “In addition, we employed AlphaFold 3 to perform energy minimization and predict hydrogen bonds between the C1QBP N-terminus (amino acids 1-167) and the PA28γ protein interaction region. The results suggest that the T76 and G78 residues of C1QBP may be key contributors to the interaction. Consistently, coimmunoprecipitation analysis demonstrated that mutations at these sites (C1QBPT76A and C1QBPG78N) significantly reduced the binding ability to PA28γ (Fig. 1J and Appendix Fig. 1J)”, specifically in results section. We believe this additional validation strengthens the robustness of our findings.</p>
<p>(2) According to your suggestion, we have added a description of the results of PLA in the figure legend (Revised Figure 1C) and the method of PLA in the appendix file (Revised Appendix file, Part “Proximity Ligation Assay”). The revised text reads as follows: (C) PLA image of UM1 cells shows the interaction between C1QBP and PA28γ in both cytoplasm and nucleus (red fluorescence).</p>
<p>(3) In the light of your suggestion, we have enriched the description of AlphaFold 3 analysis in the appendix file (Revised Appendix file, Page 10-11). The revised text reads as follows:</p>
<p>“Prediction and Analysis of Protein Interactions</p>
<p>Protein Sequence Retrieval and Structure Prediction</p>
<p>The protein sequences of C1QBP and PA28γ were obtained from the AlphaFold Protein Structure Database. Structural predictions of the protein-protein interaction between C1QBP and PA28γ were conducted using AlphaFold 3. The plDDT (predicted local distance difference test) values were utilized to assess the confidence of the predicted models. Models with a plDDT score above 70 were considered confident, while those with a score above 90 were categorized as very high confidence. These values were annotated in the figures to indicate the reliability of the structural predictions.”</p>
<p>“Protein Preparation and Structure Optimization</p>
<p>The best-scored model for the C1QBP-PA28γ interaction predicted by AlphaFold 3 was selected for further analysis. The model was imported into MOE 2022 (Molecular Operating Environment) software for protein preparation. This process included the removal of water molecules and other heteroatoms, followed by the addition of hydrogen atoms to the structure. This step was essential for optimizing the protein’s 3D conformation and ensuring the correctness of the protonation states at physiological pH.”</p>
<p>“Energy Minimization and Hydrogen Bond Prediction</p>
<p>The protein structure was subjected to energy minimization using the Amber10: EHT (Effective Hamiltonian Theory) force field, with R-field 1: 80 settings to refine the model’s geometry. The minimization process was performed to optimize the protein’s internal energy and ensure stable conformation, followed by calculation of hydrogen bond interactions. The interaction energies and hydrogen bonds were analyzed to identify potential binding sites and stabilize the predicted protein-protein complex.”</p>
</body>
</sub-article>
</article>